attachment
attachment

What antibiotic to use in this case

Reading File
Finding Sources
Finding Sources
Searching PubMed

Citrobacter freundii urinary tract infection colistin treatment

Reading File
Finding Sources
Based on the culture report, here is a thorough clinical analysis:

Urine Culture Analysis - Prakash Thapa (38M)

What the Report Shows

Two organisms isolated, both at >10^5 cfu/mL (significant bacteriuria):
  1. Citrobacter freundii - with Antimicrobial Susceptibility Test (AST) results shown
  2. Acinetobacter calcoaceticus-baumannii complex - AST results cut off (not visible in image)

Citrobacter freundii Sensitivity Pattern

AntibioticResult
Colistin SulphateI (Intermediate), MIC ≤1 µg/mL
AmikacinR
AmoxicillinR
Amoxicillin+Clavulanic AcidR
Ampicillin+SulbactamR
AztreonamR
CefepimeR
CefiximeR
CeftazidimeR
Ceftazidime+AvibactamR
CeftriaxoneR
CiprofloxacinR
Co-trimoxazoleR
DoxycyclineR
GentamicinR
ImipenemR
LevofloxacinR
MeropenemR
Piperacillin+TazobactamR
This is an extensively drug-resistant (XDR) Citrobacter freundii - resistant to ALL tested antibiotics including carbapenems (imipenem + meropenem), with only Colistin showing intermediate susceptibility.

Antibiotic Recommendation

For the Citrobacter freundii (visible results):
The only active agent is Colistin Sulphate (Polymyxin E) with an intermediate MIC of ≤1 µg/mL.
For a urinary tract infection, colistin can be appropriate because:
  • Colistin is renally excreted and achieves high urinary concentrations, which can overcome intermediate MIC results in the urinary tract
  • This is an important consideration - a drug showing "I" (intermediate) in serum may still be effective in urine due to concentration effect
Recommended regimen:
  • Colistin (Colistimethate sodium / CMS) IV or oral colistin sulphate, dosed based on renal function
  • Typical IV dose: 2.5-5 mg/kg/day of colistin base activity (CBA), divided every 8-12 hours, adjusted for eGFR
  • For uncomplicated UTI: oral colistin sulphate (not well absorbed systemically, but active locally in gut/urine) is sometimes used
Important additional steps:
  1. Check the Acinetobacter baumannii AST - the report is cut off. If colistin is sensitive for both organisms, a single agent may suffice. This organism is known to commonly be colistin-susceptible when pan-resistant otherwise.
  2. Combination therapy consideration: For XDR organisms, some authorities recommend Colistin + Fosfomycin (if susceptibility tested) or Colistin + Rifampicin for enhanced efficacy, though evidence is mixed for UTI.
  3. Fosfomycin - this was NOT tested in the susceptibility panel. Request fosfomycin susceptibility testing, as it retains activity against many MDR gram-negatives and is concentrated in urine. It is an excellent oral option for XDR UTIs.
  4. Nitrofurantoin - also not tested; worth requesting for lower UTI if infection is uncomplicated (not effective for upper UTI/urosepsis).

Clinical Priority Points

  • This patient has a polymicrobial XDR UTI - a serious situation requiring infectious disease consultation
  • Determine if this is lower UTI (cystitis) vs. upper UTI (pyelonephritis/urosepsis) - this changes management significantly
  • Colistin is nephrotoxic - monitor renal function closely
  • The MIC of ≤1 µg/mL for colistin is at the susceptible/intermediate border per EUCAST; CLSI often interprets MIC ≤2 as susceptible for some organisms
  • Request fosfomycin susceptibility urgently - if sensitive, oral fosfomycin 3g single dose (for cystitis) or extended course is a far safer alternative
Bottom line: Colistin is your only confirmed active antibiotic here. Request fosfomycin and nitrofurantoin susceptibility testing before initiating treatment if the patient is clinically stable. If the patient is septic, start IV colistin immediately with infectious disease consultation.

Murray & Nadel's Textbook of Respiratory Medicine - MDR Acinetobacter: "infections frequently require combinations of colistin with meropenem, tigecycline, or aminoglycosides" (though meropenem is resistant here, combination may still have synergy in some studies)

The patient doesn’t have fever. He is under suprapubic catheterization

Finding Sources
Searching PubMed

catheter associated bacteriuria asymptomatic treatment antibiotics

Reading File
Reading File
This context changes everything. Here is the revised recommendation:

Revised Assessment: No Antibiotic Treatment Needed

The Key Clinical Point: Asymptomatic Bacteriuria (ASB)

A patient with a suprapubic catheter and no fever, no symptoms (no flank pain, no rigors, no pelvic discomfort, no altered mental status) with a positive urine culture = Asymptomatic Bacteriuria (ASB), NOT a true urinary tract infection.
As Harrison's (22nd ed.) states directly:
"The presence of asymptomatic bacteriuria often leads to improper antimicrobial treatment in patients with indwelling urinary catheters. Apart from pregnant patients, most others need not undergo urine culture or treatment for asymptomatic bacteriuria."
Tintinalli's Emergency Medicine confirms:
"Antibiotic treatment of asymptomatic bacteriuria in a patient with a short-term indwelling urinary catheter is not recommended, unless the patient is pregnant or a urologic procedure is immediately pending."

What to Do Instead

ActionRationale
Do NOT prescribe antibioticsNo symptomatic infection to treat; treatment drives resistance
Assess whether the catheter is still neededCatheter removal is the most effective intervention
If catheter in place >14 days, replace itRemoves the biofilm reservoir; may clear bacteriuria
Repeat culture only if symptoms developFever, rigors, flank pain, hematuria, pelvic pain
Do NOT reculture to confirm clearanceThis perpetuates the "treat-reculture-escalate" cycle

When Would Antibiotics Be Justified Here?

Treat only if the patient develops any of the following (IDSA CA-UTI criteria):
  • New onset fever (>38°C)
  • Rigors / chills
  • Altered mental status (with no other cause)
  • Flank pain / costovertebral angle tenderness
  • Pelvic discomfort
  • Acute hematuria
  • If a urologic procedure (e.g., cystoscopy, catheter change under infected conditions) is planned imminently
If treatment does become necessary at that point, then Colistin (the only active agent) becomes relevant - but that decision belongs to the future.

Bottom Line

This culture represents colonization, not infection. Treating an XDR organism in an asymptomatic catheterized patient with nephrotoxic colistin would cause harm without benefit. The correct answer right now is: no antibiotic, consider catheter removal or replacement.
  • Harrison's Principles of Internal Medicine, 22E - Catheter-associated urinary tract infections
  • Tintinalli's Emergency Medicine - Complications of Urinary Catheters

The patient is diagnosed with psychosis NOS and has frank pus in catheter

Finding Sources
Finding Sources
Searching PubMed

colistin fosfomycin XDR catheter UTI treatment

Finding Sources
Searching PubMed

colistin fosfomycin combination multidrug resistant gram negative UTI

Reading File
Searching PubMed

colistin urinary tract infection extensively drug resistant Citrobacter

Now the picture is complete and clear. Here is the full revised assessment:

Revised Assessment: Active Infection - Treatment IS Required

Why This Is Now a True Infection

Frank pus in the catheter = pyuria = objective evidence of active infection, not mere colonization. The absence of fever is explained by two reasons:
  1. Psychosis NOS - the patient cannot reliably report subjective symptoms (dysuria, pelvic pain, malaise)
  2. Immunosuppression from antipsychotic medications can blunt fever response
This patient meets criteria for symptomatic catheter-associated UTI (CA-UTI) - pus is an objective finding that stands on its own.

Treatment Plan

Step 1 - Immediate (Do Right Now)

Replace or remove the suprapubic catheter. This is non-negotiable:
  • The catheter biofilm harbors XDR organisms protected from antibiotics
  • Replacing it removes the primary source
  • Do this before or simultaneously with starting antibiotics, not after

Step 2 - Send Additional Susceptibility Tests

Before or alongside starting treatment, urgently request sensitivity to agents not tested in this panel:
Agent to TestWhy
FosfomycinConcentrated in urine, often active against XDR gram-negatives, oral option
NitrofurantoinActive against some resistant organisms in lower UTI
TigecyclineBroad XDR coverage (though poor urinary levels - less useful here)
Polymyxin BCross-checks colistin activity

Step 3 - Antibiotic Treatment

Based on current sensitivity results, the only active agent is Colistin.

Regimen:

Colistin (as Colistimethate Sodium / CMS) IV:
ParameterDetail
DrugColistimethate sodium (CMS) IV
Loading dose300 mg CBA (colistin base activity) as a single loading dose
Maintenance dose2.5-5 mg/kg/day CBA in 2-3 divided doses, adjusted to renal function
Duration7-14 days for complicated catheter-associated UTI
MonitoringSerum creatinine daily, urine output, neurotoxicity signs
Critical note on "Intermediate" MIC: The colistin MIC was ≤1 µg/mL. For urinary infections, colistin achieves urine concentrations of 25-200 µg/mL after IV dosing - far exceeding the MIC. What appears "intermediate" systemically is effectively susceptible in the urinary tract. This makes colistin a rational choice specifically for UTI.

If fosfomycin comes back sensitive:

  • Fosfomycin IV 8g q8h or oral fosfomycin trometamol 3g every 48-72h (extended course for complicated UTI)
  • Fosfomycin + Colistin combination has synergistic data for XDR organisms and reduces colistin nephrotoxicity by allowing lower colistin doses

For the Acinetobacter baumannii complex (AST results were cut off in the report):

  • Obtain the full AST for the Acinetobacter - it almost certainly also shows colistin as the only active agent
  • If both organisms are colistin-susceptible (intermediate or better), a single agent covers both

Summary of Action Steps

  1. Replace the suprapubic catheter now
  2. Request fosfomycin and nitrofurantoin susceptibility urgently
  3. Start IV Colistin (CMS) - loading dose then maintenance, dose-adjusted for renal function
  4. Monitor renal function daily - colistin is nephrotoxic, especially in combination with antipsychotics (some of which are also nephrotoxic)
  5. Obtain the full Acinetobacter AST from the lab (it was cut off in the report)
  6. Infectious disease consultation - XDR polymicrobial UTI in a psychiatric patient warrants specialist input

Lippincott Illustrated Reviews Pharmacology - Polymyxins: "reserved for treatment of multidrug-resistant pathogens... Careful dosing and monitoring of adverse effects are important to maximize safety and efficacy" Tintinalli's Emergency Medicine - Catheter-associated UTI: "Remove or replace the catheter... give empiric antibiotics... tailor therapy once culture results are available"

Searcg

It looks like your message got cut off. What would you like me to search for?

What antibiotic to use

Based on everything already established in this case, here is the direct answer:

Antibiotic to Use

Colistin (Colistimethate Sodium / CMS) IV

This is the only antibiotic with activity against the XDR Citrobacter freundii in this patient. Every other tested antibiotic is resistant (R).

Practical Dosing

Loading dose300 mg colistin base activity (CBA) IV - single dose
Maintenance2.5-5 mg/kg/day CBA in 2-3 divided doses
Adjust forRenal function (check creatinine first)
Duration10-14 days for complicated CA-UTI with pus

Why Colistin Works Here Despite "Intermediate" Result

The MIC was ≤1 µg/mL. Colistin achieves urine concentrations of 25-200 µg/mL after IV dosing - vastly exceeding the MIC. Intermediate systemically = effectively sensitive in urine.

Do Alongside Antibiotics

  • Replace the suprapubic catheter (biofilm will sabotage any antibiotic otherwise)
  • Request fosfomycin susceptibility - if sensitive, add it to colistin for synergy and to reduce colistin nephrotoxicity
  • Monitor creatinine daily - colistin is nephrotoxic
  • Get complete Acinetobacter AST (that part of the report was cut off)

One-line answer: Start IV Colistimethate Sodium + replace the catheter.

Can I start Durataz for the time being

No. Do not start Durataz.
Durataz is Piperacillin + Tazobactam - and looking back at the sensitivity report, it is clearly listed as R (Resistant) for both organisms.

Why It Won't Work

OrganismPip-Tazo Result
Citrobacter freundiiR
Acinetobacter baumannii complexLikely R (consistent with XDR pattern)
Citrobacter freundii carries an inducible AmpC beta-lactamase - this enzyme is not inhibited by tazobactam. The organism will be resistant even if the disc test initially looked borderline. Piperacillin-tazobactam will not clear this infection.

What to Do Instead

There is no safe "empiric while waiting" option here - the culture and sensitivity are already back. You don't need to guess anymore.
Start Colistin IV directly. That is the definitive answer from the culture.
If IV colistin is not immediately available at your center:
  • Contact pharmacy urgently for Colistimethate Sodium (CMS)
  • Consider urgent ID/urology referral while sourcing the drug
  • Replace the catheter in the meantime - this alone reduces bacterial load
Starting an antibiotic the organism is resistant to would give false reassurance while the infection progresses.
This is a shared conversation. Sign in to Orris to start your own chat.